High grade gliomas affect patients across age groups, and this project seeks to better understand high grade gliomas as they affect pediatric, adolescent, and young adult populations. The goal of this project is to generate single cell sequencing data of cancer cells, immune cells and non-immune microenvironment in pediatric and adolescent and young adult high-grade gliomas. Researchers hypothesize that combining analysis of single-cell techniques, the microenvironment, and the immune factors of tumors and matched preclinical models will lead to a better understanding of these diseases. Deeper understanding will then promote the development of more effective therapeutics to improve outcomes for patients. The Children's Brain Tumor Network provides a unique resource of samples and data necessary for this project.
What are the goals of this project?
Researchers will generate a map of tumor cells using single cell assays and conduct comprehensive analysis on high grade gliomas in order to generate data that will be integral to the development of new therapies.
What is the impact of this project?
This project takes a comprehensive approach that will lead to a much better understanding of high grade gliomas, how they differ across age groups, and what new therapeutic options should be pursued.
Why is the CBTN request important to this project?
The Children’s Brain Tumor Network will provide this project with rare pediatric tumor samples and data from the Pediatric Brain Tumor Atlas that is not accessible elsewhere.
The Children's Brain Tumor Network contributed to this project by providing tissue samples.
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a
Children’s Hospital of Philadelphia
Aaron Diaz, PhD
Cancer Biology & Cell SignalingDevelopmental & Stem Cell Biology
UCSF Benioff Children's Hospital
Michael Prados, MD
Michael Prados began his career in Neuro-Oncology as a Fellow at the University of California San Francisco in 1985. Following a two year training program, he was recruited to the Faculty in 1988 and has remained at UCSF since that time, and holds the Charles B Wilson Chair in Neurosurgery. His care
UCSF Benioff Children's Hospital
Michelle Monje, MD, PhD
Michelle Monje, MD, PhD joined the faculty at Stanford University in 2011 as an Assistant Professor of Neurology & Neurological Sciences. Following her undergraduate degree in biology at Vassar College, Dr. Monje received her MD and PhD in Neuroscience from Stanford University. She then completed ne
Lucile Packard Children's Hospital Stanford
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
UCSF Benioff Children's HospitalJoined on
The Pediatric Brain Tumor Center at UCSF Benioff Children’s Hospital, with campuses in San Francisco and Oakland, harnesses the power of world-class experts from all disciplines related to child brain health, including neurology, neurosurgery, neurocritical care, neurogenetics, neuro-oncology, rehab
Lucile Packard Children's Hospital StanfordJoined on
Lucile Packard Children’s Hospital Stanford opened in 1991 and is the heart and soul of Stanford Children’s Health. Nationally ranked and internationally recognized, the 361-bed hospital located in Palo Alto, Calif. is devoted entirely to pediatrics and obstetrics.The Pediatric Neuro-Oncology progra
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Children's Brain Tumor Network Pediatric Brain Tumor Proteomics Pilot
Pediatric brain tumors are the leading cause of disease related death in children. Major factors contributing to treatment failures for children with brain tumors include: i) the lack of comprehensive molecular description of the disease and an associated dearth of integration of the tumors’ biologi
Craniopharyngioma, Medulloblastoma, HGG, (AT/RT), LGG, Ependymoma, Ganglioglioma, DNET, Schwannoma